MYGN Myriad Genetics Inc.

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please register . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Kate Schraml

(224) 875-4493



EN
27/10/2025

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Commercially Launches Precise MRD with Select Community Oncolog...

Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...

March 2, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
VRSK Verisk Analytic...
VNO Vornado Realty ... ... (+59)

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

VRSK VERISK ANALYTICS INC
VNO VORNADO REALTY TRUST
TYL TYLER TECHNOLOGIES INC.
TBI TRUEBLUE INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PODD INSULET CORPORATION
NEU NEWMARKET CORPORATION
MYGN MYRIAD GENETICS INC.
MSCI MSCI INC. CLASS A
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HMN HORACE MANN EDUCATORS CORPORATION
HCI HCI GROUP INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
CEVA CEVA INC.
CAR AVIS BUDGET GROUP INC.
OFIX ORTHOFIX INTERNATIONAL N.V.
WY WEYERHAEUSER COMPANY
TZOO TRAVELZOO
FIVN FIVE9 INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
SXC SUNCOKE ENERGY INC.
WINA WINMARK CORP.
ITIC INVESTORS TITLE CO.
GGT THE GABELLI MULTIMEDIA TRUST
CNDT CONDUENT INC.
HLNE HAMILTON LANE INCORPORATED CLASS A
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
BOTJ BANK OF THE JAMES FINANCIAL GROUP INC.
UBER UBER TECHNOLOGIES INC.
AVTR AVANTOR
VERX INC.
BIGC VERTEX
NBR INC.
SLQT BIGCOMMERCE HOLDINGS
DLHC NABORS INDUSTRIES LTD.
ABCL SELECTQUOTE
CVRX INC.
ELF DALEIGH HOLDINGS CORP
FLYW ABCELLERA BIOLOGICS
BLCO CVRX
FSCO INC.
CADL E.L.F. BEAUTY
CVI INC.
TLSI FLYWIRE CORP
ASST BAUSCH + LOMB CORP
EKSO FS CREDIT OPPORTUNITIES CORP.
LNZA CANDEL THERAPEUTICS
INC.
CVR ENERGY
INC.
TRISALUS LIFE SCIENCES INC
ASSET ENTITIES INC.
EKSO BIONICS HOLDINGS INC.
LANZATECH GLOBAL INC
03/02/26 March 2, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
REXR Rexford Industr...
MYGN Myriad Genetics... ... (+9)

InsiderInsights.com Daily Ratings Report: February 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

REXR REXFORD INDUSTRIAL REALTY INC.
MYGN MYRIAD GENETICS INC.
HTGC HERCULES CAPITAL INC.
HMN HORACE MANN EDUCATORS CORPORATION
WINA WINMARK CORP.
AXR AMREP
ABCL ABCELLERA BIOLOGICS
WRB W.R. BERKLEY CORPORATION
FSCO FS CREDIT OPPORTUNITIES CORP.
02/28/26 February 28, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...

February 24, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Re...

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, H...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch